^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    XIAP antagonist

    Related drugs:
    1d
    ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Institute of Cancer Research, United Kingdom | Recruiting --> Active, not recruiting | Trial completion date: Mar 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TERT (Telomerase Reverse Transcriptase)
    |
    HER-2 positive • ER positive • HER-2 negative • EGFR amplification • IDH wild-type • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Keytruda (pembrolizumab) • tolinapant (ASTX660)
    3ms
    ASTX660-01: Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas (clinicaltrials.gov)
    P1/2, N=253, Active, not recruiting, Taiho Oncology, Inc. | Trial completion date: Dec 2025 --> Dec 2027
    Trial completion date
    |
    tolinapant (ASTX660)
    4ms
    A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma (clinicaltrials.gov)
    P1/2, N=8, Terminated, Otsuka Pharmaceutical Co., Ltd. | N=61 --> 8
    Enrollment change
    |
    tolinapant (ASTX660)
    4ms
    ASTX660-03: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (clinicaltrials.gov)
    P1, N=33, Active, not recruiting, Taiho Oncology, Inc. | Phase classification: P1/2 --> P1 | Trial completion date: Dec 2026 --> Mar 2026
    Phase classification • Trial completion date
    |
    Inqovi (decitabine/cedazuridine) • tolinapant (ASTX660)
    6ms
    Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Emory University | Trial completion date: Oct 2025 --> Jul 2026
    Trial completion date
    |
    tolinapant (ASTX660)
    11ms
    Safety and Tolerability of NOX66 in Combination With Palliative Radiotherapy in Patients With Late-Stage Prostate Cancer (clinicaltrials.gov)
    P1, N=25, Completed, Noxopharm Limited | Phase classification: P1b --> P1
    Phase classification
    |
    Veyonda (idronoxil)
    1year
    Early-phase trial of IAP antagonist tolinapant and definitive radiation in cisplatin-ineligible patients with advanced head and neck cancer. (PubMed, Clin Cancer Res)
    Tolinapant + RT is well tolerated and induced proliferation of activated T cells in a subset of patients. Larger prospective studies are needed to better assess efficacy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    tolinapant (ASTX660)
    over1year
    Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Emory University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    tolinapant (ASTX660)
    over1year
    ASTX660-03: A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL) (clinicaltrials.gov)
    P1/2, N=33, Active, not recruiting, Taiho Oncology, Inc. | N=132 --> 33 | Trial primary completion date: Dec 2025 --> Dec 2024
    Enrollment change • Trial primary completion date
    |
    Inqovi (decitabine/cedazuridine) • tolinapant (ASTX660)
    over1year
    Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=42, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting
    Enrollment open
    |
    RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
    |
    eribulin mesylate • tolinapant (ASTX660)
    over1year
    The IAP antagonist tolinapant enhances the anti-tumor activity of cell therapies. (PubMed, Eur J Pharmacol)
    Our study suggests that the combination of tolinapant improves the efficacy of cell-based cancer therapies by inducing both cancer cell death and CAR-T cell proliferation. This combination therapy may overcome the current limitations of cell-based therapies and enhance their anti-cancer effect.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    tolinapant (ASTX660)
    over1year
    Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=42, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension
    |
    RIPK1 (Receptor Interacting Serine/Threonine Kinase 1)
    |
    eribulin mesylate • tolinapant (ASTX660)